---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-019455"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2023-05-30T23:59:59+00:00"
generated_at: "2026-06-14T11:30:20.800511+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# INVO Bioscience receives Nasdaq delisting notice for failure to meet $2.5M equity minimum

## Summary
- Nasdaq notified INVO on May 23, 2023, of non-compliance with Listing Rule 5550(b)(1) requiring $2.5M stockholders' equity.
- Company failed to regain compliance by the May 22, 2023 extension deadline.
- INVO plans to request a hearing before the Nasdaq Hearings Panel to stay delisting.
- No assurance that the Panel will grant continued listing or an extension.
- Stockholders' equity deficiency triggers potential delisting from Nasdaq Global Market.

## SEC filing metadata
- accession: 0001493152-23-019455
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2023-05-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315223019455/0001493152-23-019455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315223019455/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-019455
- JSON: https://secwatch.observer/filing/0001493152-23-019455.json
- Plain text: https://secwatch.observer/filing/0001493152-23-019455.txt

## Key facts
- Listing & Compliance Notices
  INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: May 23, 2023, INVO Bioscience, Inc. (the “Company”) was notified by the Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Rule”), as of May 22, 2023, the Company’s common stock was subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing be
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223019455/0001493152-23-019455-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.